Orthofix Medical Inc.

No, Orthofix Medical Inc. is not a private company. It is a publicly traded global medical technology enterprise listed on the Nasdaq Global Select Market under the ticker symbol OFIX.

Yes, Orthofix's core medical devices and bone growth therapy systems are FDA approved or cleared for commercial distribution and clinical use in the United States.

The global orthopedic and medical device market features several massive multinational corporations competing for top market share.

When referring to pharmaceutical products like the OFIX tablet (which contains the fluoroquinolone antibiotic ofloxacin), potential side effects can include gastrointestinal discomfort such as nausea, mild diarrhea, abdominal cramps, headaches, dizzi...

Orthofix Medical Inc. is recognized as an established global medical technology enterprise dedicated to advancing spine and orthopedic care solutions.

Depending on the context of your inquiry, OFIX can refer to multiple distinct entities. In financial markets, OFIX is the ticker symbol for Orthofix Medical Inc.

Yes, Medicare generally covers non-invasive bone growth stimulators, but authorization is strictly contingent upon meeting precise medical necessity criteria.

Revo Health operates as a prominent management services organization partnering with specialized healthcare practices like Twin Cities Orthopedics.

In orthopedic and medical device contexts, specialized systems carrying similar names are deployed to stimulate bone healing.

Yes, Medicare generally covers bone growth stimulators, but coverage is strictly regulated and contingent upon meeting precise medical necessity criteria.

When discussing medical devices or orthopedic care frameworks, "Safix" (or similar variant terminology associated with casting, bandaging, or stabilization products) typically presents minimal localized risks.

The corporate net worth or market capitalization of Orthofix Medical Inc. (NASDAQ: OFIX) fluctuates dynamically during active trading hours on the Nasdaq exchange based on share price changes and total outstanding common stock.

Orthofix Medical Inc.

Orthofix Medical Inc. maintains its primary corporate headquarters and executive administrative offices in Lewisville, Texas, United States.

The prescribed duration for wearing a non-invasive bone growth stimulator varies significantly based on the specific anatomical location of the fracture, the severity of the non-union or spinal fusion, and the attending physician's clinical instructi...

Clinical and scientific evidence demonstrates that Orthofix's medical devices and orthopedic systems achieve high rates of clinical efficacy when utilized according to strict manufacturer guidelines and physician instructions.

Bone growth stimulators are generally considered exceptionally safe medical devices with minimal adverse side effects.

Wall Street equity research analysts covering Orthofix Medical Inc. (NASDAQ: OFIX) maintain a general consensus rating leaning toward a Buy.

The "best" bone growth stimulator is determined by a physician's prescription based on the specific type of fracture, non-union status, or spinal fusion site.

The out-of-pocket rental cost for a prescription bone growth stimulator varies significantly depending on health insurance coverage, Medicare provider fee schedules, and specific device models.

The Ofix 200 Tablet is a prescription fluoroquinolone antibiotic containing 200mg of ofloxacin as its active pharmaceutical ingredient.

The financial cost of an Orthofix bone growth stimulator varies substantially depending on whether the device is rented or purchased, insurance contract terms, and specific Medicare fee schedules.

Orthofix Medical Inc. maintains a dedicated global workforce comprising approximately 1,300 to 1,600 employees worldwide.